Meigene completed 167 million RMB rounds of financing

The main target of the Xiamen-based company is genetic testing for end consumers and clinics, targeting health internventions, drug development etc.

China Bio news release, October 26, 2016

Meigene completed 167 million RMB rounds of financing
Scroll to top